ABVC BioPharma has announced significant operational enhancements at its BioKey subsidiary's 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley, positioning the site as a central component of the company's global chemistry, manufacturing, and controls strategy. The Fremont, California facility incorporates formulation development laboratories, analytical laboratories, quality-aligned production areas, and warehousing, with capacity for expansion to accommodate multiple development programs simultaneously within a single integrated U.S. location.
The facility operates as a single-location, multi-product development center supporting pharmaceutical formulations, botanical and plant-based products, controlled-release and specialized solid-oral dosage forms, and functional food and nutraceutical products. All activities from formulation through pilot-scale preparation are performed entirely within the United States, providing a fully domestic development pathway that reduces cross-border complexities and enhances supply-chain resilience. This domestic approach addresses growing concerns about international supply chain vulnerabilities in pharmaceutical manufacturing.
BioKey's operational capabilities include formulation development for pharmaceuticals and functional food products, process development and pilot-scale preparation, analytical testing, stability studies, quality documentation, and technical and regulatory support for U.S. and international submissions. The integrated structure enables simultaneous support of multiple therapeutic and nutraceutical projects under coordinated oversight, creating efficiencies in drug development timelines.
The expansion outlook through 2030 represents one of the most significant aspects of this development, with ABVC anticipating that BioKey's expanded activities, operational growth, and partner-supported programs will support up to 1,000 jobs across formulation, analytical development, quality operations, regulatory support, documentation, data management, and supply-chain coordination. This job creation potential comes at a time when the biotechnology sector continues to be a major driver of economic growth in California's innovation economy.
With over 12,054 square feet of expansion-ready space, the Fremont site can accommodate additional analytical capacity, expanded development and production workflows, technology-transfer and documentation centers, and functional food and clinical material preparation zones. The facility's design supports ABVC's medium-term development plan targeting expanded U.S.-Asia chemistry, manufacturing, and controls execution and increased participation in global pharmaceutical and functional food innovation.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that "BioKey is an essential pillar of ABVC's global development strategy. Our 28,176-square-foot Silicon Valley facility provides a fully U.S.-based platform capable of supporting multiple pharmaceutical, botanical, and functional food programs from early formulation through pilot preparation." The company's broader pipeline includes six drugs and one medical device under development, utilizing technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
Investors can find more detailed information about the company and risk factors in the Company's filings with the Securities and Exchange Commission available at https://www.sec.gov. The expansion of domestic pharmaceutical manufacturing capacity addresses critical supply chain concerns that emerged during recent global health challenges, potentially reducing dependence on international manufacturing for essential medicines and health products.
